Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425022
Status:
UNKNOWN
Last Update Posted:
2007-01-30
First Post:
2007-01-19
Brief Title:
VATS Lobectomy for Clinical Stage IB or II Lung Cancer
Sponsor:
National Cancer Center Korea
Organization:
National Cancer Center Korea
Study Overview
Official Title:
Feasibility of VATSVideo-Assisted Thoracoscopic Surgery Lobectomy for Clinical Stage IB or II Non-Small Cell Lung Cancer
Status:
UNKNOWN
Status Verified Date:
2007-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To examine the feasibility of VATS lobectomy for clinical stage IB or II non-small cell lung cancer Success is defined as VATS lobectomy without conversion If success rate over 90 VATS lobectomy is considered as feasible procedures for clinical stage IB or II non-small cell lung cancer
Detailed Description:
Video-assisted or minimally invasive surgery has become the standard approach for many abdominal surgical operations such as cholecystectomy and fundoplication With respect to the thorax video-assisted thoracoscopic surgeryVATS is the accepted technique for biopsy of the lung and pleura and surgical treatment of pneumothoraxThoracoscopic also termed video-assisted thoracoscopic lobectomy has become accepted as a safe and effective procedure to treat early-stage non-small cell lung cancer NSCLC Several pilot series of thoracoscopic lobectomy in stage I lung cancer patients have been reported demonstrating low complication rates and effective short-term and long-term oncologic results With increasing experience the indications for thoracoscopic lobectomy have been expanded Single and Multi-institutional studies have demonstrated that thoracoscopic lobectomy is not only a safe and feasible technique but is also associated with decreased morbidity including shorter length of hospitalization and chest tube duration decreased postoperative pain improved preservation of pulmonary function reduced inflammatory response as measured by lower postoperative cytokine levels and shorter recovery time as compared with conventional thoracotomy The advantages of thoracoscopic lobectomy have been demonstrated in patients with clinical stage I NSCLC and this strategy has been found to be particularly useful for specific subsets of patients such as the elderly and those patients with poor performance status
The purpose of this study is to know whether VATS lobectomy for clinical stage IB or II non-small cell lung cancer is possible
The purpose of this study is to know whether VATS lobectomy for clinical stage IB or II non-small cell lung cancer is possible
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None